Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margreet G Franken

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
JAMA Network Open|March 29, 2021
Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple MyelomaHedwig M Blommestein, Margreet G Franken, Chrissy H Y van Beurden-Tan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based studyBrenda Leeneman, Kay Schreuder, Carin A Uyl-de Groot, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2012
Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The NetherlandsMargreet G Franken, Chantal W M van Gils, Jennifer G Gaultney, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 15, 2017
Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch ExperiencesSaskia de Groot, Naomi van der Linden, Margreet G Franken, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 16, 2019
Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanomaBrenda Leeneman, Margreet G Franken, Veerle M H Coupé, et al.
Melanoma Research|April 19, 2021
Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the NetherlandsBrenda Leeneman, Hedwig M Blommestein, Veerle M H Coupé, et al.
Cancers|May 13, 2020
Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic TherapyStephanie A Blankenstein, Maureen J B Aarts, Franchette W P J van den Berkmortel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2025
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic modelHedwig M Blommestein, Saskia de Groot, Brenda Leeneman, et al.
Cancers|April 25, 2020
Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted DrugsBrenda Leeneman, Carin A Uyl-de Groot, Maureen J B Aarts, et al.
Melanoma Research|May 12, 2018
Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomesMaartje G Schouwenburg, Anouk Jochems, Brenda Leeneman, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
JAMA Network Open|March 29, 2021
Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple MyelomaHedwig M Blommestein, Margreet G Franken, Chrissy H Y van Beurden-Tan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based studyBrenda Leeneman, Kay Schreuder, Carin A Uyl-de Groot, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2012
Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The NetherlandsMargreet G Franken, Chantal W M van Gils, Jennifer G Gaultney, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 15, 2017
Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch ExperiencesSaskia de Groot, Naomi van der Linden, Margreet G Franken, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 16, 2019
Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanomaBrenda Leeneman, Margreet G Franken, Veerle M H Coupé, et al.
Melanoma Research|April 19, 2021
Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the NetherlandsBrenda Leeneman, Hedwig M Blommestein, Veerle M H Coupé, et al.
Cancers|May 13, 2020
Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic TherapyStephanie A Blankenstein, Maureen J B Aarts, Franchette W P J van den Berkmortel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2025
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic modelHedwig M Blommestein, Saskia de Groot, Brenda Leeneman, et al.
Cancers|April 25, 2020
Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted DrugsBrenda Leeneman, Carin A Uyl-de Groot, Maureen J B Aarts, et al.
Melanoma Research|May 12, 2018
Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomesMaartje G Schouwenburg, Anouk Jochems, Brenda Leeneman, et al.
Pageof 3